Ambience Healthcare raises $70M in round led by OpenAI Startup Fund and Kleiner Perkins

A financing round for healthcare workflows

Ambience Healthcare announced a $70 million Series B on February 6, 2024, co-led by Kleiner Perkins and OpenAI Startup Fund. Existing investors included Optum Ventures and Andreessen Horowitz. The announcement named the Startup Fund specifically, rather than describing the financing as a direct OpenAI acquisition or product launch.

Ambience described software for clinical documentation and related administrative work. Its announced suite included generating visit notes, supporting documentation and coding review, preparing referral letters and producing after-visit summaries. The company framed those functions as connected workflows rather than a standalone tool for replacing clinical judgment.

The roadmap and outcome claims need separate treatment

The release listed a pre-visit preparation product, AutoPrep, as coming soon. It also said the funding would accelerate the product roadmap and build dedicated teams for health-system partners. Those plans were not proof that every proposed capability had already shipped.

The company's claims about time savings, financial returns and adoption were not an independent clinical or operational audit. Investor confidence and customer testimonials do not establish that every generated note is accurate or every coding suggestion appropriate. The announcement did not justify treating the software as an autonomous provider of care.

Review the handoff from conversation to record

Analysis: documentation software should be evaluated at the point where a draft becomes a record someone relies on. A useful review asks what was captured, what was inferred and how a clinician can correct an omission or a mistaken detail before it travels into another workflow.

The same information may later support a referral, a patient summary or an administrative process, so an early error can matter beyond the first note. Trace those handoffs and the responsibility for review. That provides a more concrete way to assess the platform than assuming a funding round proves reliability across every specialty and setting.